AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 41 min read$CODX

Co-Diagnostics, Inc. (CODX): Submission of Matters to a Vote of Security Holders

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). However, the Company did not achieve a quorum and therefore was unable t

Original reporting
SEC EDGAR 8-K
Published Sep 4, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$CODX
Neutral
high confidence
Mentioned
$CODX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CODXNeutralLow
01

Why it matters

The filing provides no new financial data; it merely informs shareholders of a procedural delay.

02

Market read

Minimal impact; primarily a governance notice for existing shareholders.

03

What to watch

Potential proxy battles or upcoming shareholder proposals at the reconvened meeting.

Relevance 6/10Novelty 3/10Timing: adjourned meeting set for Sep 24 2026

Background

Co‑Diagnostics filed a Form 8‑K under Item 5.07 to disclose that its annual shareholder meeting lacked a quorum and was rescheduled.

Company-level read

Ticker impact

$CODXNeutralHigh confidence
Context

SEC 8‑K reports that Co‑Diagnostics failed to achieve a quorum at its annual meeting and has adjourned it to Sep 24, 2026.

Expected impact

Limited short‑term impact; price may stay flat until the reconvened meeting.

Evidence & confidence

No material business change disclosed; only procedural delay.

Market effects

Sector

None; filing is specific to Co‑Diagnostics.

Regional

None; limited to company shareholders.

Global

None

Counterpoint

What could challenge this read

Investors could view the quorum failure as a red flag for governance issues.

Key entities

  • company
    Co‑Diagnostics, Inc.

    Medical diagnostics company filing the 8‑K.

  • person
    Dwight Egan

    CEO who signed the filing.

Read at source← All news

Related articles

AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

prnewswire.com6 min
AUG 13
$CODXMed

Co-Diagnostics, Inc. (CODX): Results of Operations and Financial Condition

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

SEC EDGAR 8-K6 min
AUG 13
$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.

stocktitan.net6 min
AUG 6
$CODXMed

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Co-Diagnostics (Nasdaq: CODX) said it submitted a Dual 510(k) premarket notification with a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The filing follows clinical studies of 1,400 symptomatic patients and analytical work across 27 studies and 10,000+ PCR runs. If granted, the CLIA waiver would enable decentralized point-of-care use; the platform is not yet for sale.

prnewswire.com2 min
MAY 29
$SPRCMedAI 8/10

Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

rttnews.com6 min